Best Practice and Research. Clinical Haematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Christina Kalpadakis, Gerassimos A. Pangalis, Maria K. Angelopoulou, Sotirios Sachanas, Theodoros P. VassilakopoulosAbstractBackgroundSMZL is a relatively rare low grade B-cell lymphoma, characterized usually by an indolent clinical behavior. Since there is no prospective randomized trials to establish the best treatment approach, decision on therapeutic management should be based on the available retrospective series. Based on these data, rituximab and splenectomy appear to be the most effective. Splenectomy rep...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Risk stratification in follicular lymphoma
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Carla CasuloAbstractAdvances in the understanding of FL biology, molecular characteristics and clinical risk factors are further highlighting the heterogeneity of this disease. Historically used prognostic factors were broadly based on clinical and laboratory features at the time of diagnosis. However novel prognostic factors are emerging that can be studied at the time of diagnosis, and relapse, and use a variety of tools including gene alterations and diagnostic imaging. These novel discoveries are being implem...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Management of untreated advanced stage follicular lymphoma: Role of patient discernment
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Jayadev Manikkam Umakanthan, Mathew A. LunningAbstractFollicular lymphoma is the most common indolent non-Hodgkin lymphoma. Advanced stage disease is common at diagnosis. The timing of treatment for follicular lymphoma is best approached by considering the combination of presence or absence of symptoms along with estimation of tumor burden. Upfront treatment strategies should take into initial presentation variables, pace of disease progression and goals of care after discussion with the patient. Treatment approa...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

The role of stem cell transplantation in follicular lymphoma
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Georg HessAbstractWith the introduction of novel treatments paradigms to if or when to use transplantation strategies for patients with follicular lymphoma have changed substantially. Autologous transplantation has been intensively evaluated as consolidation after first induction treatment with positive effects, however the introduction of Rituximab led to comparable improvements and HDT has been moved to relapse treatment. In this indication HDT was frequently use already at first relapse, but now is dominantly ...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Novel agents for relapsed and refractory follicular lymphoma
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Chan Yoon Cheah, Nathan H. FowlerAbstractFollicular lymphoma is one of the most common non-Hodgkin's lymphomas. Although current frontline regimens are associated with high response rates, most patients still relapse. When progression is discovered, re-establishing the diagnosis and ruling out transformation in paramount. The outcomes following relapse have been improving due to the activity and increasing availability of novel agents with various mechanisms of action. Despite these advances, single agent activit...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Transformation of follicular lymphoma – Why does it happen and can it be prevented?
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Brian K. LinkAbstractFollicular lymphoma is a clinical disease with a multitude of presentations and behaviors. Although infrequent, transformation of follicular lymphoma to a more aggressive behaving subtype – prototypically diffuse large B-cell lymphoma – confers a substantially adverse prognosis. There is no consensus for optimal management after transformation is recognized. Historically considered a distinct clinical event, this review highlights the multiple subclinical transformational events that eith...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Overview on the management of non-gastric MALT lymphomas
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Irene Defrancesco, Luca ArcainiAbstractExtranodal marginal zone B-cell lymphomas (EMZLs) of the mucosa-associated lymphoid tissue (MALT) are indolent lymphomas which can present at any extranodal site. The most frequent localizations (other than stomach) are ocular adnexa, salivary gland, skin, lung and thyroid. Chronic inflammation and antigenic stimulation are a potential risk for the development of MALT lymphomas. While Helicobacter Pylori (HP) is known to be associated with gastric MALT lymphoma and antibioti...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

What is the optimal management of older CLL patients?
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Jennifer A. WoyachAbstractCLL is the most common leukemia in older adults with a median age at diagnosis of 71. Therefore, management of patients with this disease must take into account the older age of most patients and consequences of this in terms of functional status and organ function. This review will discuss the management of CLL with regards to observation prior to the initiation of therapy, functional status, and initial treatment. We will discuss criteria for the initiation of therapy, and how initial ...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Pathogenesis of follicular lymphoma
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Tracy Lackraj, Rashmi Goswami, Robert KridelAbstractFollicular lymphoma (FL) is presented as a germinal centre B cell lymphoma that is characterized by an indolent clinical course, but remains – paradoxically – largely incurable to date. The last years have seen significant progress in our understanding of FL lymphomagenesis, which is a multi-step process beginning in the bone marrow with the hallmark t(14;18)(q32;q21) translocation. The pathobiology of FL is complex and combines broad somatic changes at the ...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Joana M. Murad, David J. Graber, Charles L. SentmanAbstractChimeric antigen receptors (CAR)-T cell therapy has recently made promising advances towards treatment of B-cell malignancies. This approach makes use of an antibody-derived single chain variable fragment (scFv)-based CAR to target the CD19 antigen. Currently scFvs are the most common strategy for creation of CARs, but tumor cells can also be targeted using non-antibody based approaches with designs focused on the interaction between natural receptors and ...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

CARs and other T cell therapies for MM: The clinical experience
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Sophia Danhof, Michael Hudecek, Eric L. SmithAbstractHarnessing the endogenous immune system to eliminate malignant cells has long been an intriguing approach. After considerable success in the treatment of B-cell acute lymphoblastic leukemia, chimeric antigen receptor (CAR)-modified T cells have entered early clinical evaluation in the field of multiple myeloma (MM). The choice of suitable non-CD19 target antigens is challenging and a variety of myeloma-associated surface molecules have been under preclinical inv...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Toxicities associated with immunotherapies for hematologic malignancies
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Mark B. Leick, Marcela V. MausAbstractImmunotherapy has generated tremendous hope for patients with cancer that is refractory to standard approaches. Hematologic malignancies have taken the lead in harnessing the most recent advances in cell-based immunotherapies, such as CAR T cells, and some patients have achieved durable remissions. However, these T-cell-engaging therapies are associated with a new set of toxicities which need to be managed by caretakers, oncologists, nurses, and healthcare staff. In this revie...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Off the shelf T cell therapies for hematologic malignancies
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Bruce J. McCreedy, Vladimir V. Senyukov, Kim T. NguyenAbstractAdoptive transfer of autologous CAR-T cells can induce durable remissions in patients with relapsed/refractory hematologic malignancies. However, multiple challenges exist for manufacturing CAR-T cells from patients with advanced disease including inability to manufacture a product, disease progression or death while waiting for the CAR-T product to be available, and heterogeneity among autologous CAR-T products that contributes to unpredictable and var...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Index
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Editorial Board / Aims & Scope
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research